Recent News

• 03.31.2026 - Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
• 03.30.2026 - Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
• 03.16.2026 - Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
• 03.10.2026 - Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• 03.03.2026 - Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Recent Filings

• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2026 - 144 Report of proposed sale of securities
• 03.17.2026 - 144 Report of proposed sale of securities
• 03.17.2026 - 144 Report of proposed sale of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities